Metsera, Inc. (NASDAQ:MTSR - Get Free Report) was up 13.4% during trading on Monday . The company traded as high as $27.12 and last traded at $27.08. Approximately 432,115 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 861,302 shares. The stock had previously closed at $23.87.
Analysts Set New Price Targets
Several equities analysts recently weighed in on MTSR shares. Guggenheim initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $56.00 target price for the company. Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price for the company. Cantor Fitzgerald began coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an "overweight" rating for the company. Finally, Evercore ISI initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating on the stock.
Check Out Our Latest Stock Report on MTSR
Metsera Stock Up 10.5%
The company's 50 day simple moving average is $22.80.
Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Institutional Investors Weigh In On Metsera
A number of large investors have recently modified their holdings of MTSR. New York State Common Retirement Fund purchased a new position in shares of Metsera in the first quarter worth $131,000. Invesco Ltd. purchased a new position in shares of Metsera during the 1st quarter valued at approximately $271,000. Deutsche Bank AG purchased a new position in Metsera in the first quarter valued at $374,000. Bank of New York Mellon Corp purchased a new position in Metsera in the first quarter valued at $884,000. Finally, TD Asset Management Inc acquired a new position in shares of Metsera in the first quarter worth about $2,091,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
